Yale-Led Team Develops Nanosensors for Detecting Biomarkers in Whole Blood | GenomeWeb

This story originally ran on Jan. 6.

By Tony Fong

A team of researchers led by Yale scientists has created a nanosensor device that they said can detect cancer protein biomarkers in whole blood for the first time, representing a "paradigm shift in label-free electronic sensing of biomolecules."

The researchers have launched a company, Altura Diagnostics, to explore opportunities to commercialize the technology, but the firm is still in the very early stages of development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.